All 1 tracked stories fall under one category: clinical-trial. Jill Smokler is most often covered alongside American Brain Tumor Association, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention Jill Smokler, all published on July 25, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Jill Smokler
All 1 tracked stories fall under one category: clinical-trial. Jill Smokler is most often covered alongside American Brain Tumor Association, which appears in 1 of these 1 story. We currently track 1 Biotech story that mention Jill Smokler, all published on July 25, 2026. Each carries 5 original sources on average.
Stories tracked
1
Sources per story
5
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 15 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Jill Smokler. Shared-story counts are live from our verified record — not editorial picks.
Annual glioblastoma diagnoses exceed 12,000 with a grim sub-two-year life expectancy, spotlighting a high-priority target for biotech investment and therapeutic innovation. Dr. Annick Desjardins' awareness messaging underscores the rapid proliferation and clinical chaos that keep this disease among oncology’s toughest nuts to crack.